NAD refers Maxam Nutraceuticals to FTC
NEW YORK — The National Advertising Division has referred advertising claims made by Maxam Nutraceuticals for its PCA dietary supplement to the Federal Trade Commission for further review, after the company declined to participate in a review of its claims.
The Council for Responsible Nutrition challenged claims made by Maxam in television and Internet advertising, including:
- “PCA is the only product ever specifically developed to naturally help your body safely and effectively remove all toxins, poisons, chemicals or anything that is not part of a healthy living biological system.”;
- “PCA has been used and proven over the last 15 years to be the most effective toxin remover available.”; and
- “Through our SMART Selective Micro-Activated Response Technology, the ingredients remain in their natural form, which keeps the liver from repelling them, allowing them to effectively work with your body.”
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.
Green Pharmaceuticals generates brand awareness with controversial ad campaign
NEW YORK — Green Pharmaceuticals has drummed up some brand awareness for its SnoreStop stop-snoring solution with a controversial ad on Sunset Blvd. in Los Angeles, The Daily News reported last week.
The ad depicts an American soldier and Muslim woman who is wearing a wedding band accompanied by the hash-tag #betogether. "With this new campaign, we wanted to celebrate diversity, celebrate equality … by bringing into our campaign values coming from every corner of life," reported Christian DeRivel, Green Pharmaceutical chief branding officer, in a behind-the-scenes video on the campaign.
This is not the first time Green Pharmaceuticals has generated buzz for its brands through a newsworthy ad campaign. In 2005, Green paid more than $37,000 for the right to tattoo an advertisement on the forehead of Andrew Fischer. Fischer had placed his advertising real estate up for bid on eBay. Fischer sported a temporary SnoreStop tattoo for 30 days.
Reuters: Question on whether emergency contraceptives less effective in women weighing more than 165 lbs.
NEW YORK — The Food and Drug Administration is reviewing emergency contraceptives like Plan B One-Step on whether they are less effective in women weighing more than 165 lbs., according to a report published Monday by Reuters.
FDA’s impetus was the fact that European health regulators recently required a label change communicating that a similar emergency contraceptive began losing effectiveness in women who weighed 165 lbs. The emergency contraceptive did not work for women weighing more than 176 lbs, Reuters reported.
The emergency contraceptive that came under question in Europe is HRA Pharma’s Norlevo.